At the recent 4th National Aids Conference, Dr Charles Hicks, Senior Global Medical Director, ViiV Healthcare, US, spoke about the evolution of HIV care and how future advancements will impact the lives of persons living with HIV. Hicks, who is only recently joined ViiV Healthcare, said the cure for HIV is still likely far in the future. In the meantime, the only option is antiretroviral therapy (ART). However, despite the absence of a cure, the outlook for patients living with HIV has improved by leaps and bounds since the first antiretroviral zidovudine (AZT) was released.
Treatment with the combination of the DAAs* glecaprevir and pibrentasvir led to sustained virological response (SVR) in a majority of patients with chronic hepatitis C virus (HCV) infection genotype 5 or 6, according to the phase IIIB ENDURANCE-5,6** trial.
The implementation of point-of-care testing (POCT) for viral respiratory infections in emergency departments could reduce unnecessary hospitalizations and antibiotic treatment, according to a study from the UK.
The airway microbiota is recently demonstrated to be associated with lung cancer via up-regulation of the ERK, PI3K and IL-17A signalling pathways, according to data presented at the recent European Respiratory Society (ERS) International Congress 2018.
Preterm infants who tested positive for ureaplasma respiratory tract infection had poorer survival over the first year of life, according to a study presented at ERS 2018. However, a 3-day course of prophylactic azithromycin could potentially reduce this morbidity and mortality burden.
Teenagers and young adults living with perinatally acquired HIV (PaHIV) have a higher risk of developing malignancies and a higher all-cause mortality rate than their non-HIV-infected peers, according to a study from the UK.